Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Europe Syndromic Multiplex Diagnostic Market - Industry Trends Forecast to 2027

Published by Data Bridge Market Research Private Limited Product code 961987
Published Content info 162 Pages
Delivery time: 1-2 business days
Price
Back to Top
Europe Syndromic Multiplex Diagnostic Market - Industry Trends Forecast to 2027
Published: August 1, 2020 Content info: 162 Pages
Description

Europe syndromic multiplex diagnostic market is projected to register a CAGR of 7.0% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.

Market Segmentation:

Europe Syndromic Multiplex Diagnostic Market By Products and Services (Reagents & Consumables, Instruments & Accessories, Software & Services), Infection Type (Viral, Bacterial, Parasites, Fungal, Others, Disease (Respiratory Infections, Gastroenteritis, Sexually Transmitted Infections, Hepatitis, Tropical Fever, Meningitis, Childhood Infections, Immunosuppression, Eye Infections), Panels Type (Respiratory Panel, GI-Enteric Panel, Sexually Transmitted Disease Panel, Blood-Sepsis Panel, Meningitis Panel, Others), End User (Hospitals, Clinical Laboratories, Pharmaceutical & Biotechnology Companies, Research Institutes, Physician Office Lab's, Others) Country (Germany, U.K., France, Italy, Spain, Switzerland, Netherlands, Belgium, Russia, Turkey & Rest of Europe) Industry Trends and Forecast to 2027

Some of the major factors contributing to the growth of Europe Syndromic Multiplex Diagnostic market are

Growing prevalence of infection diseases

Growing adoption of molecular diagnostics and increasing demand for accurate and fast diagnostic results

Market Players:

The key market players for Europe syndromic multiplex diagnostic market are listed below:

GenMark Diagnostics, Inc.

QuantuMDx Group Ltd.

BioFire Diagnostics (a subsidiary of bioMerieux SA)

Bio-Rad Laboratories, Inc.

Thermo Fisher Scientific Inc.

Siemens Healthcare GmbH

QIAGEN

Hologic, Inc.

F. Hoffmann-La Roche Ltd

BD

Danaher

Curetis

Abbott

DiaSorin S.p.A.

Bosch Healthcare Solutions GmbH (a subsidiary of Robert Bosch GmbH)

Biocartis, Luminex Corporation

Seegene Inc.

Table of Contents

TABLE OF CONTENTS

1 INTRODUCTION 16

  • 1.1 OBJECTIVES OF THE STUDY 16
  • 1.2 MARKET DEFINITION 16
  • 1.3 OVERVIEW OF EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET 17
  • 1.4 LIMITATIONS 18
  • 1.5 MARKETS COVERED 18

2 MARKET SEGMENTATION 20

  • 2.1 MARKETS COVERED 20
  • 2.2 GEOGRAPHICAL SCOPE 21
  • 2.3 YEARS CONSIDERED FOR THE STUDY 21
  • 2.4 CURRENCY AND PRICING 21
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL 22
  • 2.6 MULTIVARIATE MODELLING 25
  • 2.7 PRODUCTS AND SERVICES LIFELINE CURVE 25
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 26
  • 2.9 DBMR MARKET POSITION GRID 27
  • 2.10 VENDOR SHARE ANALYSIS 28
  • 2.11 SECONDARY SOURCES 29
  • 2.12 ASSUMPTIONS 29

3 EXECUTIVE SUMMARY 30

4 PREMIUM INSIGHTS 32

5 MARKET OVERVIEW 34

  • 5.1 DRIVERS 36
    • 5.1.1 GROWING PREVALENCE OF INFECTION DISEASES 36
    • 5.1.2 GROWING ADOPTION OF MOLECULAR DIAGNOSTICS 37
    • 5.1.3 INCREASING REGULATORY APPROVAL FOR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) TESTING 38
    • 5.1.4 INCREASING DEMAND FOR ACCURATE AND FAST DIAGNOSTIC RESULTS 39
    • 5.1.5 IMPROVING DIAGNOSIS SEEKING RATE 40
  • 5.2 RESTRAINTS 40
    • 5.2.1 HIGH COST OF DIAGNOSTIC PRODUCTS 40
    • 5.2.2 EXPLICIT LIMITATION OF SYNDROMIC MULTIPLEX DIAGNOSTIC 41
  • 5.3 OPPORTUNITIES 41
    • 5.3.1 INCREASING DIAGNOSTIC HEALTHCARE EXPENDITURE 41
    • 5.3.2 INTRODUCTION OF TECHNOLOGICALLY ADVANCED PRODUCTS 42
  • 5.4 CHALLENGES 42
    • 5.4.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF DIAGNOSTIC PRODUCTS 42
    • 5.4.2 LACK OF SKILLED PROFESSIONALS AND BARRIERS FACED IN CONDUCTING DIAGNOSTIC TESTS 43

6 IMPACT OF COVID-19 ON EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET 44

  • 6.1 IMPACT ANALYSIS ON DEMAND 44
  • 6.2 CONCLUSION 45

7 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES 46

  • 7.1 OVERVIEW 47
  • 7.2 REAGENTS & CONSUMABLES 50
  • 7.3 INSTRUMENTS & ACCESSORIES 50
  • 7.4 SOFTWARE & SERVICES 50

8 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE 52

  • 8.1 OVERVIEW 53
  • 8.2 VIRAL 55
    • 8.2.1 RHINOVIRUS 56
    • 8.2.2 ROTAVIRUS 56
    • 8.2.3 ADENOVIRUS 56
    • 8.2.4 CORONAVIRUS 56
    • 8.2.5 OTHERS 56
  • 8.3 BACTERIAL 57
    • 8.3.1 PNEUMONIAE 57
    • 8.3.2 BORDETELLA PERTUSSIS 57
    • 8.3.3 STAPHYLOCOCCUS 58
    • 8.3.4 OTHERS 58
  • 8.4 PARASITES 58
  • 8.5 FUNGAL 58
  • 8.6 OTHERS 59

9 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE 60

  • 9.1 OVERVIEW 61
  • 9.2 RESPIRATORY INFECTIONS 64
  • 9.3 GASTROENTERITIS 65
  • 9.4 SEXUALLY TRANSMITTED INFECTIONS 65
  • 9.5 HEPATITIS 65
  • 9.6 TROPICAL FEVER 66
  • 9.7 MENINGITIS 67
  • 9.8 CHILDHOOD INFECTIONS 67
  • 9.9 IMMUNOSUPPRESSION 67
  • 9.10 EYE INFECTIONS 68

10 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE 69

  • 10.1 OVERVIEW 70
  • 10.2 RESPIRATORY PANEL 73
  • 10.3 GI-ENTERIC PANEL 73
  • 10.4 SEXUALLY TRANSMITTED DISEASE PANEL 73
  • 10.5 BLOOD-SEPSIS PANEL 74
  • 10.6 MENINGITIS PANEL 74
  • 10.7 OTHERS 74

11 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER 75

  • 11.1 OVERVIEW 76
  • 11.2 HOSPITALS 79
  • 11.3 CLINICAL LABORATORIES 79
  • 11.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 79
  • 11.5 RESEARCH INSTITUTES 80
  • 11.6 PHYSICS OFFICE LAB'S 81
  • 11.7 OTHERS 81

12 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY COUNTRY 82

  • 12.1 OVERVIEW 83
    • 12.1.1 GERMANY 89
    • 12.1.2 U.K. 92
    • 12.1.3 FRANCE ` 95
    • 12.1.4 ITALY 98
    • 12.1.5 SPAIN 101
    • 12.1.6 SWITZERLAND 104
    • 12.1.7 NETHERLANDS 107
    • 12.1.8 RUSSIA 110
    • 12.1.9 BELGIUM 113
    • 12.1.10 TURKEY 116
    • 12.1.11 REST OF EUROPE 119

13 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, COMPANY LANDSCAPE 120

  • 13.1 COMPANY SHARE ANALYSIS: EUROPE 120

14 SWOT ANALYSIS 121

15 COMPANY PROFILE 122

  • 15.1 BIOFIRE DIAGNOSTICS (A SUBSIDIARY OF BIOMERIEUX SA) 122
    • 15.1.1 COMPANY SNAPSHOT 122
    • 15.1.2 REVENUE ANALYSIS 122
    • 15.1.3 PRODUCT PORTFOLIO 123
    • 15.1.4 RECENT DEVELOPMENTS 124
  • 15.2 SIEMENS HEALTHCARE GMBH 125
    • 15.2.1 COMPANY SNAPSHOT 125
    • 15.2.2 REVENUE ANALYSIS 125
    • 15.2.3 PRODUCT PORTFOLIO 126
    • 15.2.4 RECENT DEVELOPMENTS 126
  • 15.3 F. HOFFMANN-LA ROCHE LTD 127
    • 15.3.1 COMPANY SNAPSHOT 127
    • 15.3.2 REVENUE ANALYSIS 127
    • 15.3.3 PRODUCT PORTFOLIO 128
    • 15.3.4 RECENT DEVELOPMENT 128
  • 15.4 THERMO FISHER SCIENTIFIC INC. 129
    • 15.4.1 COMPANY SNAPSHOT 129
    • 15.4.2 REVENUE ANALYSIS 129
    • 15.4.3 PRODUCT PORTFOLIO 130
    • 15.4.4 RECENT DEVELOPMENT 130
  • 15.5 BD 131
    • 15.5.1 COMPANY SNAPSHOT 131
    • 15.5.2 REVENUE ANALYSIS 131
    • 15.5.3 PRODUCT PORTFOLIO 132
    • 15.5.4 RECENT DEVELOPMENTS 132
  • 15.6 SEEGENE INC. 133
    • 15.6.1 COMPANY SNAPSHOT 133
    • 15.6.2 REVENUE ANALYSIS 133
    • 15.6.3 PRODUCT PORTFOLIO 134
    • 15.6.4 RECENT DEVELOPMENTS 136

  • 15.7 ABBOTT 137
    • 15.7.1 COMPANY SNAPSHOT 137
    • 15.7.2 REVENUE ANALYSIS 137
    • 15.7.3 PRODUCT PORTFOLIO 138
    • 15.7.4 RECENT DEVELOPMENT 138
  • 15.8 BIOCARTIS 139
    • 15.8.1 COMPANY SNAPSHOT 139
    • 15.8.2 REVENUE ANALYSIS 139
    • 15.8.3 PRODUCT PORTFOLIO 140
    • 15.8.4 RECENT DEVELOPMENT 140
  • 15.9 BIO-RAD LABORATORIES, INC. 141
    • 15.9.1 COMPANY SNAPSHOT 141
    • 15.9.2 REVENUE ANALYSIS 141
    • 15.9.3 PRODUCT PORTFOLIO 142
    • 15.9.4 RECENT DEVELOPMENT 142
  • 15.10 BOSCH HEALTHCARE SOLUTIONS GMBH (A SUBSIDIARY OF ROBERT BOSCH GMBH) 143
    • 15.10.1 COMPANY SNAPSHOT 143
    • 15.10.2 REVENUE ANALYSIS 143
    • 15.10.3 PRODUCT PORTFOLIO 144
    • 15.10.4 RECENT DEVELOPMENT 144
  • 15.11 CURETIS 145
    • 15.11.1 COMPANY SNAPSHOT 145
    • 15.11.2 PRODUCT PORTFOLIO 145
    • 15.11.3 RECENT DEVELOPMENT 145
  • 15.12 DANAHER 146
    • 15.12.1 COMPANY SNAPSHOT 146
    • 15.12.2 REVENUE ANALYSIS 146
    • 15.12.3 PRODUCT PORTFOLIO 147
    • 15.12.4 RECENT DEVELOPMENT 147
  • 15.13 DIASORIN S.P.A. 148
    • 15.13.1 COMPANY SNAPSHOT 148
    • 15.13.2 REVENUE ANALYSIS 148
    • 15.13.3 PRODUCT PORTFOLIO 149
    • 15.13.4 RECENT DEVELOPMENTS 149
  • 15.14 GENMARK DIAGNOSTICS, INC. 150
    • 15.14.1 COMPANY SNAPSHOT 150
    • 15.14.2 REVENUE ANALYSIS 150
    • 15.14.3 PRODUCT PORTFOLIO 151
    • 15.14.4 RECENT DEVELOPMENTS 151

  • 15.15 HOLOGIC, INC. 152
    • 15.15.1 COMPANY SNAPSHOT 152
    • 15.15.2 REVENUE ANALYSIS 152
    • 15.15.3 PRODUCT PORTFOLIO 153
    • 15.15.4 RECENT DEVELOPMENTS 153
  • 15.16 LUMINEX CORPORATION 154
    • 15.16.1 COMPANY SNAPSHOT 154
    • 15.16.2 REVENUE ANALYSIS 154
    • 15.16.3 PRODUCT PORTFOLIO 155
    • 15.16.4 RECENT DEVELOPMENT 155
  • 15.17 QIAGEN 156
    • 15.17.1 COMPANY SNAPSHOT 156
    • 15.17.2 REVENUE ANALYSIS 156
    • 15.17.3 PRODUCT PORTFOLIO 157
    • 15.17.4 RECENT DEVELOPMENT 157
  • 15.18 QUANTUMDX GROUP LTD. 158
    • 15.18.1 COMPANY SNAPSHOT 158
    • 15.18.2 PRODUCT PORTFOLIO 158
    • 15.18.3 RECENT DEVELOPMENT 158

16 QUESTIONNAIRE 159

17 RELATED REPORTS 162

LIST OF TABLES

  • TABLE 1 COST OF THE PRODUCT 40
  • TABLE 2 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2018-2027 (USD MILLION) 49
  • TABLE 3 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION) 55
  • TABLE 4 EUROPE VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION) 56
  • TABLE 5 EUROPE BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION) 57
  • TABLE 6 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2018-2027 (USD MILLION) 64
  • TABLE 7 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, LIFELINE CURVE, 2018-2027 (USD MILLION) 72
  • TABLE 8 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2018-2027 (USD MILLION) 78
  • TABLE 9 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY COUNTRY, 2018-2027 (USD MILLION) 86
  • TABLE 10 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2018-2027 (USD MILLION) 86
  • TABLE 11 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION) 86
  • TABLE 12 EUROPE VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION) 87
  • TABLE 13 EUROPE BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION) 87
  • TABLE 14 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2018-2027 (USD MILLION) 87
  • TABLE 15 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2018-2027 (USD MILLION) 88
  • TABLE 16 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2018-2027 (USD MILLION) 88
  • TABLE 17 GERMANY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2018-2027 (USD MILLION) 89
  • TABLE 18 GERMANY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION) 89
  • TABLE 19 GERMANY VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION) 89
  • TABLE 20 GERMANY BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION) 90
  • TABLE 21 GERMANY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2018-2027 (USD MILLION) 90
  • TABLE 22 GERMANY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2018-2027 (USD MILLION) 90
  • TABLE 23 GERMANY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2018-2027 (USD MILLION) 91
  • TABLE 24 U.K. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2018-2027 (USD MILLION) 92
  • TABLE 25 U.K. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION) 92
  • TABLE 26 U.K. VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION) 92
  • TABLE 27 U.K. BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION) 93
  • TABLE 28 U.K. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2018-2027 (USD MILLION) 93
  • TABLE 29 U.K. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2018-2027 (USD MILLION) 93
  • TABLE 30 U.K. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2018-2027 (USD MILLION) 94
  • TABLE 31 FRANCE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2018-2027 (USD MILLION) 95
  • TABLE 32 FRANCE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION) 95
  • TABLE 33 FRANCE VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION) 95
  • TABLE 34 FRANCE BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION) 96
  • TABLE 35 FRANCE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2018-2027 (USD MILLION) 96
  • TABLE 36 FRANCE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2018-2027 (USD MILLION) 96
  • TABLE 37 FRANCE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2018-2027 (USD MILLION) 97
  • TABLE 38 ITALY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2018-2027 (USD MILLION) 98
  • TABLE 39 ITALY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION) 98
  • TABLE 40 ITALY VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION) 98
  • TABLE 41 ITALY BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION) 99
  • TABLE 42 ITALY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2018-2027 (USD MILLION) 99
  • TABLE 43 ITALY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2018-2027 (USD MILLION) 99
  • TABLE 44 ITALY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2018-2027 (USD MILLION) 100
  • TABLE 45 SPAIN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2018-2027 (USD MILLION) 101
  • TABLE 46 SPAIN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION) 101
  • TABLE 47 SPAIN VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION) 101
  • TABLE 48 SPAIN BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION) 102
  • TABLE 49 SPAIN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2018-2027 (USD MILLION) 102
  • TABLE 50 SPAIN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2018-2027 (USD MILLION) 102
  • TABLE 51 SPAIN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2018-2027 (USD MILLION) 103
  • TABLE 52 SWITZERLAND SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2018-2027 (USD MILLION) 104
  • TABLE 53 SWITZERLAND SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION) 104
  • TABLE 54 SWITZERLAND VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION) 104
  • TABLE 55 SWITZERLAND BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION) 105
  • TABLE 56 SWITZERLAND SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2018-2027 (USD MILLION) 105
  • TABLE 57 SWITZERLAND SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2018-2027 (USD MILLION) 105
  • TABLE 58 SWITZERLAND SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2018-2027 (USD MILLION) 106
  • TABLE 59 NETHERLANDS SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2018-2027 (USD MILLION) 107
  • TABLE 60 NETHERLANDS SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION) 107
  • TABLE 61 NETHERLANDS VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION) 107
  • TABLE 62 NETHERLANDS BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION) 108
  • TABLE 63 NETHERLANDS SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2018-2027 (USD MILLION) 108
  • TABLE 64 NETHERLANDS SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2018-2027 (USD MILLION) 108
  • TABLE 65 NETHERLANDS SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2018-2027 (USD MILLION) 109
  • TABLE 66 RUSSIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2018-2027 (USD MILLION) 110
  • TABLE 67 RUSSIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION) 110
  • TABLE 68 RUSSIA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION) 110
  • TABLE 69 RUSSIA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION) 111
  • TABLE 70 RUSSIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2018-2027 (USD MILLION) 111
  • TABLE 71 RUSSIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2018-2027 (USD MILLION) 111
  • TABLE 72 RUSSIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2018-2027 (USD MILLION) 112
  • TABLE 73 BELGIUM SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2018-2027 (USD MILLION) 113
  • TABLE 74 BELGIUM SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION) 113
  • TABLE 75 BELGIUM VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION) 113
  • TABLE 76 BELGIUM BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION) 114
  • TABLE 77 BELGIUM SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2018-2027 (USD MILLION) 114
  • TABLE 78 BELGIUM SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2018-2027 (USD MILLION) 114
  • TABLE 79 BELGIUM SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2018-2027 (USD MILLION) 115
  • TABLE 80 TURKEY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2018-2027 (USD MILLION) 116
  • TABLE 81 TURKEY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION) 116
  • TABLE 82 TURKEY VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION) 116
  • TABLE 83 TURKEY BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION) 117
  • TABLE 84 TURKEY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2018-2027 (USD MILLION) 117
  • TABLE 85 TURKEY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2018-2027 (USD MILLION) 117
  • TABLE 86 TURKEY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2018-2027 (USD MILLION) 118
  • TABLE 87 REST OF EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2018-2027 (USD MILLION) 119

LIST OF FIGURES

  • FIGURE 1 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SEGMENTATION 20
  • FIGURE 2 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: DATA TRIANGULATION 22
  • FIGURE 3 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: DROC ANALYSIS 23
  • FIGURE 4 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET : EUROPE VS REGIONAL MARKET ANALYSIS 24
  • FIGURE 5 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET : COMPANY RESEARCH ANALYSIS 24
  • FIGURE 6 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS 26
  • FIGURE 7 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: DBMR MARKET POSITION GRID 27
  • FIGURE 8 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS 28
  • FIGURE 9 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SEGMENTATION 31
  • FIGURE 10 GROWING PREVALENCE OF INFECTION DISEASES AND GROWING ADOPTION OF MOLECULAR DIAGNOSTICS ARE EXPECTED TO DRIVE THE EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET IN THE FORECAST PERIOD OF 2020 TO 2027 32
  • FIGURE 11 REAGENTS & CONSUMABLES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET IN 2020 & 2027 32
  • FIGURE 1 GERMANY IS EXPECTED TO DOMINATE THE GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2020 TO 2027 33
  • FIGURE 2 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET 35
  • FIGURE 3 TOTAL CASES OF CORONAVIRUS IN EUROPE 36
  • FIGURE 4 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCTS AND SERVICES, 2019 47
  • FIGURE 5 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCTS AND SERVICES, 2019-2027 (USD MILLION) 48
  • FIGURE 6 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCTS AND SERVICES, CAGR (2020-2027) 48
  • FIGURE 7 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCTS AND SERVICES, LIFELINE CURVE 49
  • FIGURE 8 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, 2019 53
  • FIGURE 9 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, CAGR (2020-2027) 54
  • FIGURE 10 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, LIFELINE CURVE 55
  • FIGURE 11 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, 2019 61
  • FIGURE 12 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, 2019-2027 (USD MILLION) 62
  • FIGURE 13 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, CAGR (2020-2027) 63
  • FIGURE 14 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, LIFELINE CURVE 63
  • FIGURE 15 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, 2019 70
  • FIGURE 16 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, 2019-2027 (USD MILLION) 71
  • FIGURE 17 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, CAGR (2020-2027) 71
  • FIGURE 18 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, LIFELINE CURVE 72
  • FIGURE 19 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, 2019 76
  • FIGURE 20 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, 2019-2027 (USD MILLION) 77
  • FIGURE 21 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, CAGR (2020-2027) 77
  • FIGURE 22 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, LIFELINE CURVE 78
  • FIGURE 23 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SNAPSHOT (2019) 83
  • FIGURE 24 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2019) 84
  • FIGURE 25 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2020 & 2027) 84
  • FIGURE 26 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2020 & 2027) 85
  • FIGURE 27 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCTS AND SERVICES (2018-2027) 85
  • FIGURE 28 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: COMPANY SHARE 2019 (%) 120
Back to Top